About lecanmab
Amyloid-beta-directed monoclonal antibody
Used for
- Slows cognitive and functional decline in early Alzheimer’s disease, including mild cognitive impairment or mild dementia, with confirmed amyloid pathology.
Usual adult dose
10 mg/kg intravenously every two weeks for 18 months; maintenance dosing may follow.
Common side effects
- Infusion reactions
- Amyloid-related brain swelling or bleeding
- Headache
- Nausea
Important warnings
- Brain swelling or bleeding can be serious or fatal; MRI monitoring is required.
- Risk is higher with APOE ε4, especially two copies; testing can inform discussion.
- Use caution with anticoagulants or medicines that increase bleeding risk.
- Treatment is for early Alzheimer’s disease with confirmed amyloid; specialist assessment is needed.
Pregnancy
Human pregnancy data are insufficient; use only when clearly necessary.
Breastfeeding
It is unknown whether lecanemab enters breast milk; effects on infants are unknown.
Interactions
- Anticoagulants and thrombolytics may increase bleeding concerns, including brain bleeding.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.